Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)

Wei Fan Hsu; Pei Chein Tsai; Chi Yi Chen; Kuo Chih Tseng; Hsueh Chou Lai; Hsing Tao Kuo; Chao Hung Hung; Shui Yi Tung; Jing Houng Wang; Jyh Jou Chen; Pei Lun Lee; Ron Nan Chien; Chun Yen Lin; Chi Chieh Yang; Gin Ho Lo; Chi Ming Tai; Chih Wen Lin; Jia Horng Kao; Chun Jen Liu; Chen Hua Liu; Sheng Lei Yan; Ming Jong Bair; Wei Wen Su; Cheng Hsin Chu; Chih Jen Chen; Ching Chu Lo; Pin Nan Cheng; Yen Cheng Chiu; Chia Chi Wang; Jin Shiung Cheng; Wei Lun Tsai; Han Chieh Lin; Yi Hsiang Huang; Jee Fu Huang; Chia Yen Dai; Wan Long Chuang; Ming Lung Yu; Cheng Yuan Peng

doi:10.1111/jgh.15538

Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)

Wei Fan Hsu, Pei Chein Tsai, Chi Yi Chen, Kuo Chih Tseng, Hsueh Chou Lai, Hsing Tao Kuo, Chao Hung Hung, Shui Yi Tung, Jing Houng Wang, Jyh Jou Chen, Pei Lun Lee, Ron Nan Chien, Chun Yen Lin, Chi Chieh Yang, Gin Ho Lo, Chi Ming Tai, Chih Wen Lin, Jia Horng Kao, Chun Jen Liu, Chen Hua LiuSheng Lei Yan, Ming Jong Bair, Wei Wen Su, Cheng Hsin Chu, Chih Jen Chen, Ching Chu Lo, Pin Nan Cheng, Yen Cheng Chiu, Chia Chi Wang, Jin Shiung Cheng, Wei Lun Tsai, Han Chieh Lin, Yi Hsiang Huang, Jee Fu Huang, Chia Yen Dai, Wan Long Chuang, Ming Lung Yu^*, Cheng Yuan Peng^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

11 Scopus citations

Abstract

Background and Aim: It is currently unknown how hepatitis C virus (HCV) eradication with pegylated interferon and ribavirin (PR) therapy affects the incidence of new-onset liver cirrhosis (LC) in patients without cirrhosis and the incidence of decompensated liver disease (DLD) or hepatocellular carcinoma (HCC) in patients with cirrhosis. Methods: Taiwanese chronic hepatitis C cohort (T-COACH) is a nationwide HCV registry cohort from 23 hospitals in Taiwan recruited between 2003 and 2015. This study enrolled 10 693 patients with chronic hepatitis C (CHC), linked to the Taiwan National Health Insurance Research Database, receiving PR therapy for at least 4 weeks for new-onset LC and liver-related complications (DLD or HCC). Results: Of the 10 693 patients, 1372 (12.8%) patients had LC, and the mean age was 54.0 ± 11.4 years. The mean follow-up duration was 4.38 ± 2.79 years, with overall 46 798 person-years. The 10-year cumulative incidence rates of new-onset LC were 5.0% (95% confidence interval [CI]: 3.2–7.7) in patients without cirrhosis with a sustained virologic response (SVR) and 21.9% (95% CI: 13.4–32.4) in those without SVR (hazard ratio [HR]: 0.22, P < 0.001). The 10-year cumulative incidence rates of liver-related complications were 21.4% (95% CI: 11.1–37.2) in patients with cirrhosis with SVR and 47.0% (95% CI: 11.1–86.0) in those without SVR after adjustment for age, sex, and competing mortality (HR: 0.52, P < 0.001). Conclusions: Hepatitis C virus eradication with PR therapy decreased the incidence of new-onset LC in noncirrhotic patients and the incidence of liver-related complications in cirrhotic patients with CHC.

Original language	English
Pages (from-to)	2884-2892
Number of pages	9
Journal	Journal of Gastroenterology and Hepatology (Australia)
Volume	36
Issue number	10
DOIs	https://doi.org/10.1111/jgh.15538
State	Published - 10 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd

Keywords

T-COACH
chronic hepatitis C
decompensated liver disease
hepatocellular carcinoma
liver cirrhosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jgh.15538

Cite this

Hsu, W. F., Tsai, P. C., Chen, C. Y., Tseng, K. C., Lai, H. C., Kuo, H. T., Hung, C. H., Tung, S. Y., Wang, J. H., Chen, J. J., Lee, P. L., Chien, R. N., Lin, C. Y., Yang, C. C., Lo, G. H., Tai, C. M., Lin, C. W., Kao, J. H., Liu, C. J., ... Peng, C. Y. (2021). Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). Journal of Gastroenterology and Hepatology (Australia), 36(10), 2884-2892. https://doi.org/10.1111/jgh.15538

@article{885edb5e3bc449849fa5ac00dee363ca,

title = "Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)",

abstract = "Background and Aim: It is currently unknown how hepatitis C virus (HCV) eradication with pegylated interferon and ribavirin (PR) therapy affects the incidence of new-onset liver cirrhosis (LC) in patients without cirrhosis and the incidence of decompensated liver disease (DLD) or hepatocellular carcinoma (HCC) in patients with cirrhosis. Methods: Taiwanese chronic hepatitis C cohort (T-COACH) is a nationwide HCV registry cohort from 23 hospitals in Taiwan recruited between 2003 and 2015. This study enrolled 10 693 patients with chronic hepatitis C (CHC), linked to the Taiwan National Health Insurance Research Database, receiving PR therapy for at least 4 weeks for new-onset LC and liver-related complications (DLD or HCC). Results: Of the 10 693 patients, 1372 (12.8%) patients had LC, and the mean age was 54.0 ± 11.4 years. The mean follow-up duration was 4.38 ± 2.79 years, with overall 46 798 person-years. The 10-year cumulative incidence rates of new-onset LC were 5.0% (95% confidence interval [CI]: 3.2–7.7) in patients without cirrhosis with a sustained virologic response (SVR) and 21.9% (95% CI: 13.4–32.4) in those without SVR (hazard ratio [HR]: 0.22, P < 0.001). The 10-year cumulative incidence rates of liver-related complications were 21.4% (95% CI: 11.1–37.2) in patients with cirrhosis with SVR and 47.0% (95% CI: 11.1–86.0) in those without SVR after adjustment for age, sex, and competing mortality (HR: 0.52, P < 0.001). Conclusions: Hepatitis C virus eradication with PR therapy decreased the incidence of new-onset LC in noncirrhotic patients and the incidence of liver-related complications in cirrhotic patients with CHC.",

keywords = "T-COACH, chronic hepatitis C, decompensated liver disease, hepatocellular carcinoma, liver cirrhosis",

author = "Hsu, {Wei Fan} and Tsai, {Pei Chein} and Chen, {Chi Yi} and Tseng, {Kuo Chih} and Lai, {Hsueh Chou} and Kuo, {Hsing Tao} and Hung, {Chao Hung} and Tung, {Shui Yi} and Wang, {Jing Houng} and Chen, {Jyh Jou} and Lee, {Pei Lun} and Chien, {Ron Nan} and Lin, {Chun Yen} and Yang, {Chi Chieh} and Lo, {Gin Ho} and Tai, {Chi Ming} and Lin, {Chih Wen} and Kao, {Jia Horng} and Liu, {Chun Jen} and Liu, {Chen Hua} and Yan, {Sheng Lei} and Bair, {Ming Jong} and Su, {Wei Wen} and Chu, {Cheng Hsin} and Chen, {Chih Jen} and Lo, {Ching Chu} and Cheng, {Pin Nan} and Chiu, {Yen Cheng} and Wang, {Chia Chi} and Cheng, {Jin Shiung} and Tsai, {Wei Lun} and Lin, {Han Chieh} and Huang, {Yi Hsiang} and Huang, {Jee Fu} and Dai, {Chia Yen} and Chuang, {Wan Long} and Yu, {Ming Lung} and Peng, {Cheng Yuan}",

note = "Publisher Copyright: {\textcopyright} 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd",

year = "2021",

month = oct,

doi = "10.1111/jgh.15538",

language = "英语",

volume = "36",

pages = "2884--2892",

journal = "Journal of Gastroenterology and Hepatology (Australia)",

issn = "0815-9319",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "10",

}

Hsu, WF, Tsai, PC, Chen, CY, Tseng, KC, Lai, HC, Kuo, HT, Hung, CH, Tung, SY, Wang, JH, Chen, JJ, Lee, PL, Chien, RN, Lin, CY, Yang, CC, Lo, GH, Tai, CM, Lin, CW, Kao, JH, Liu, CJ, Liu, CH, Yan, SL, Bair, MJ, Su, WW, Chu, CH, Chen, CJ, Lo, CC, Cheng, PN, Chiu, YC, Wang, CC, Cheng, JS, Tsai, WL, Lin, HC, Huang, YH, Huang, JF, Dai, CY, Chuang, WL, Yu, ML & Peng, CY 2021, 'Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)', Journal of Gastroenterology and Hepatology (Australia), vol. 36, no. 10, pp. 2884-2892. https://doi.org/10.1111/jgh.15538

Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). / Hsu, Wei Fan; Tsai, Pei Chein; Chen, Chi Yi et al.
In: Journal of Gastroenterology and Hepatology (Australia), Vol. 36, No. 10, 10.2021, p. 2884-2892.

Research output: Contribution to journal › Journal Article › peer-review

TY - JOUR

T1 - Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)

AU - Hsu, Wei Fan

AU - Tsai, Pei Chein

AU - Chen, Chi Yi

AU - Tseng, Kuo Chih

AU - Lai, Hsueh Chou

AU - Kuo, Hsing Tao

AU - Hung, Chao Hung

AU - Tung, Shui Yi

AU - Wang, Jing Houng

AU - Chen, Jyh Jou

AU - Lee, Pei Lun

AU - Chien, Ron Nan

AU - Lin, Chun Yen

AU - Yang, Chi Chieh

AU - Lo, Gin Ho

AU - Tai, Chi Ming

AU - Lin, Chih Wen

AU - Kao, Jia Horng

AU - Liu, Chun Jen

AU - Liu, Chen Hua

AU - Yan, Sheng Lei

AU - Bair, Ming Jong

AU - Su, Wei Wen

AU - Chu, Cheng Hsin

AU - Chen, Chih Jen

AU - Lo, Ching Chu

AU - Cheng, Pin Nan

AU - Chiu, Yen Cheng

AU - Wang, Chia Chi

AU - Cheng, Jin Shiung

AU - Tsai, Wei Lun

AU - Lin, Han Chieh

AU - Huang, Yi Hsiang

AU - Huang, Jee Fu

AU - Dai, Chia Yen

AU - Chuang, Wan Long

AU - Yu, Ming Lung

AU - Peng, Cheng Yuan

PY - 2021/10

Y1 - 2021/10

N2 - Background and Aim: It is currently unknown how hepatitis C virus (HCV) eradication with pegylated interferon and ribavirin (PR) therapy affects the incidence of new-onset liver cirrhosis (LC) in patients without cirrhosis and the incidence of decompensated liver disease (DLD) or hepatocellular carcinoma (HCC) in patients with cirrhosis. Methods: Taiwanese chronic hepatitis C cohort (T-COACH) is a nationwide HCV registry cohort from 23 hospitals in Taiwan recruited between 2003 and 2015. This study enrolled 10 693 patients with chronic hepatitis C (CHC), linked to the Taiwan National Health Insurance Research Database, receiving PR therapy for at least 4 weeks for new-onset LC and liver-related complications (DLD or HCC). Results: Of the 10 693 patients, 1372 (12.8%) patients had LC, and the mean age was 54.0 ± 11.4 years. The mean follow-up duration was 4.38 ± 2.79 years, with overall 46 798 person-years. The 10-year cumulative incidence rates of new-onset LC were 5.0% (95% confidence interval [CI]: 3.2–7.7) in patients without cirrhosis with a sustained virologic response (SVR) and 21.9% (95% CI: 13.4–32.4) in those without SVR (hazard ratio [HR]: 0.22, P < 0.001). The 10-year cumulative incidence rates of liver-related complications were 21.4% (95% CI: 11.1–37.2) in patients with cirrhosis with SVR and 47.0% (95% CI: 11.1–86.0) in those without SVR after adjustment for age, sex, and competing mortality (HR: 0.52, P < 0.001). Conclusions: Hepatitis C virus eradication with PR therapy decreased the incidence of new-onset LC in noncirrhotic patients and the incidence of liver-related complications in cirrhotic patients with CHC.

AB - Background and Aim: It is currently unknown how hepatitis C virus (HCV) eradication with pegylated interferon and ribavirin (PR) therapy affects the incidence of new-onset liver cirrhosis (LC) in patients without cirrhosis and the incidence of decompensated liver disease (DLD) or hepatocellular carcinoma (HCC) in patients with cirrhosis. Methods: Taiwanese chronic hepatitis C cohort (T-COACH) is a nationwide HCV registry cohort from 23 hospitals in Taiwan recruited between 2003 and 2015. This study enrolled 10 693 patients with chronic hepatitis C (CHC), linked to the Taiwan National Health Insurance Research Database, receiving PR therapy for at least 4 weeks for new-onset LC and liver-related complications (DLD or HCC). Results: Of the 10 693 patients, 1372 (12.8%) patients had LC, and the mean age was 54.0 ± 11.4 years. The mean follow-up duration was 4.38 ± 2.79 years, with overall 46 798 person-years. The 10-year cumulative incidence rates of new-onset LC were 5.0% (95% confidence interval [CI]: 3.2–7.7) in patients without cirrhosis with a sustained virologic response (SVR) and 21.9% (95% CI: 13.4–32.4) in those without SVR (hazard ratio [HR]: 0.22, P < 0.001). The 10-year cumulative incidence rates of liver-related complications were 21.4% (95% CI: 11.1–37.2) in patients with cirrhosis with SVR and 47.0% (95% CI: 11.1–86.0) in those without SVR after adjustment for age, sex, and competing mortality (HR: 0.52, P < 0.001). Conclusions: Hepatitis C virus eradication with PR therapy decreased the incidence of new-onset LC in noncirrhotic patients and the incidence of liver-related complications in cirrhotic patients with CHC.

KW - T-COACH

KW - chronic hepatitis C

KW - decompensated liver disease

KW - hepatocellular carcinoma

KW - liver cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=85106343034&partnerID=8YFLogxK

U2 - 10.1111/jgh.15538

DO - 10.1111/jgh.15538

M3 - 文章

C2 - 33963615

AN - SCOPUS:85106343034

SN - 0815-9319

VL - 36

SP - 2884

EP - 2892

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

IS - 10

ER -

Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this